GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » BioCryst Pharmaceuticals Inc (NAS:BCRX) » Definitions » Cyclically Adjusted Price-to-FCF

BCRX (BioCryst Pharmaceuticals) Cyclically Adjusted Price-to-FCF : (As of May. 25, 2025)


View and export this data going back to 1994. Start your Free Trial

What is BioCryst Pharmaceuticals Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


BioCryst Pharmaceuticals Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for BioCryst Pharmaceuticals's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCryst Pharmaceuticals Cyclically Adjusted Price-to-FCF Chart

BioCryst Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioCryst Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioCryst Pharmaceuticals's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, BioCryst Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCryst Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, BioCryst Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where BioCryst Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


;
;

BioCryst Pharmaceuticals Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

BioCryst Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, BioCryst Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.128/134.9266*134.9266
=-0.128

Current CPI (Mar. 2025) = 134.9266.

BioCryst Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 0.231 100.684 0.310
201509 -0.175 100.392 -0.235
201512 -0.257 99.792 -0.347
201603 -0.300 100.470 -0.403
201606 -0.177 101.688 -0.235
201609 -0.241 101.861 -0.319
201612 -0.079 101.863 -0.105
201703 -0.113 102.862 -0.148
201706 -0.120 103.349 -0.157
201709 -0.151 104.136 -0.196
201712 -0.108 104.011 -0.140
201803 -0.200 105.290 -0.256
201806 -0.143 106.317 -0.181
201809 -0.333 106.507 -0.422
201812 -0.219 105.998 -0.279
201903 -0.246 107.251 -0.309
201906 -0.223 108.070 -0.278
201909 -0.251 108.329 -0.313
201912 -0.080 108.420 -0.100
202003 -0.152 108.902 -0.188
202006 -0.193 108.767 -0.239
202009 -0.218 109.815 -0.268
202012 -0.242 109.897 -0.297
202103 -0.345 111.754 -0.417
202106 -0.147 114.631 -0.173
202109 -0.132 115.734 -0.154
202112 -0.185 117.630 -0.212
202203 -0.423 121.301 -0.471
202206 -0.151 125.017 -0.163
202209 -0.175 125.227 -0.189
202212 -0.130 125.222 -0.140
202303 -0.253 127.348 -0.268
202306 -0.102 128.729 -0.107
202309 -0.110 129.860 -0.114
202312 -0.047 129.419 -0.049
202403 -0.262 131.776 -0.268
202406 -0.007 132.554 -0.007
202409 0.040 133.029 0.041
202412 -0.028 133.157 -0.028
202503 -0.128 134.927 -0.128

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


BioCryst Pharmaceuticals  (NAS:BCRX) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


BioCryst Pharmaceuticals Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of BioCryst Pharmaceuticals's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


BioCryst Pharmaceuticals Business Description

Traded in Other Exchanges
Address
4505 Emperor Boulevard, Suite 200, Durham, NC, USA, 27703
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.
Executives
Nancy J Hutson director 64 MONTAUK AVENUE, STONINGTON CT 06378
Amy E Mckee director 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703
Machelle Sanders director C/O NOVAN, INC., 4105 HOPSON ROAD, MORRISVILLE NC 27560
Theresa Heggie director 4505 EMPEROR BOULEVARD, SUITE 200, DURHAM NC 27703
Alan G Levin director ACETO CORP., 4 TRI HARBOR CT., PORT WASHINGTON NY 11050
Steve Aselage director 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Vincent Milano director C/O VIROPHARMA INC, 405 EAGLEVIEW BLVD, EXTON PA 19341
Helen M. Thackray director C/O GLYCOMIMETICS, INC., 401 PROFESSIONAL DRIVE, SUITE 250, GAITHERSBURG MD 20879
Anthony Doyle officer: Chief Financial Officer 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Steven K Galson director C/O BIOCRYST PHARMACEUTICALS, INC., 4505 EMPEROR BLVD, SUITE 200, DURHAM NC 27703
Charles K Gayer officer: Vice President and CCO 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Alane P Barnes officer: VP, General Counsel & Corp Sec 1929 BRASSFIELD ROAD, RALEIGH NC 27614
Jon P Stonehouse director, officer: CEO 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244
Michael L Jones officer: Exec Director, Finance - PAO 4505 EMPEROR BLVD., SUITE 200, DURHAM NC 27703
Yarlagadda S Babu officer: VP Drug Discovery 2190 PARKWAY LAKE DR, BIRMINGHAM AL 35244